Skip to main content
Top
Published in: BMC Gastroenterology 1/2014

Open Access 01-12-2014 | Research article

Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy

Authors: Sheng Li, Liangjun Zhu, Li Yao, Lei Xia, Liangxi Pan

Published in: BMC Gastroenterology | Issue 1/2014

Login to get access

Abstract

Background

Aim was to explore the association of ERCC1 and TS mRNA levels with the disease free survival (DFS) in Chinese colorectal cancer (CRC) patients receiving oxaliplatin and 5-FU based adjuvant chemotherapy.

Methods

Total 112 Chinese stage II-III CRC patients were respectively treated by four different chemotherapy regimens after curative operation. The TS and ERCC1 mRNA levels in primary tumor were measured by real-time RT-PCR. Kaplan–Meier curves and log-rank tests were used for DFS analysis. The Cox proportional hazards model was used for prognostic analysis.

Results

In univariate analysis, the hazard ratio (HR) for the mRNA expression levels of TS and ERCC1 (logTS: HR = 0.820, 95% CI = 0.600 - 1.117, P = 0.210; logERCC1: HR = 1.054, 95% CI = 0.852 - 1.304, P = 0.638) indicated no significant association of DFS with the TS and ERCC1 mRNA levels. In multivariate analyses, tumor stage (IIIc: reference, P = 0.083; IIb: HR = 0.240, 95% CI = 0.080 - 0.724, P = 0.011; IIc: HR < 0.0001, P = 0.977; IIIa: HR = 0.179, 95% CI = 0.012 - 2.593, P = 0.207) was confirmed to be the independent prognostic factor for DFS. Moreover, the Kaplan-Meier DFS curves showed that TS and ERCC1 mRNA levels were not significantly associated with the DFS (TS: P = 0.264; ERCC1: P = 0.484).

Conclusion

The mRNA expression of ERCC1 and TS were not applicable to predict the DFS of Chinese stage II-III CRC patients receiving 5-FU and oxaliplatin based adjuvant chemotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover J, Parkin DM, Wardle J, Duffy SW, Cuzick J: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010, 375 (9726): 1624-1633. 10.1016/S0140-6736(10)60551-X.CrossRefPubMed Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover J, Parkin DM, Wardle J, Duffy SW, Cuzick J: Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010, 375 (9726): 1624-1633. 10.1016/S0140-6736(10)60551-X.CrossRefPubMed
2.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.CrossRefPubMed Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127 (12): 2893-2917. 10.1002/ijc.25516.CrossRefPubMed
3.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61 (2): 69-90. 10.3322/caac.20107.CrossRefPubMed
4.
go back to reference de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011, 9 (5): 476-485. 10.1016/j.stem.2011.10.008.CrossRef de Sousa E, Melo F, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, Tuynman JB, Prasetyanti PR, Fessler E, van den Bergh SP: Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell. 2011, 9 (5): 476-485. 10.1016/j.stem.2011.10.008.CrossRef
5.
go back to reference Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res. 2003, 9 (10): 3700-3704.PubMed Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M: Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res. 2003, 9 (10): 3700-3704.PubMed
6.
go back to reference Rubbia-Brandt L, Audard V, Sartoretti P, Roth A, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004, 15 (3): 460-466. 10.1093/annonc/mdh095.CrossRefPubMed Rubbia-Brandt L, Audard V, Sartoretti P, Roth A, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004, 15 (3): 460-466. 10.1093/annonc/mdh095.CrossRefPubMed
7.
go back to reference Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3 (5): 330-338. 10.1038/nrc1074.CrossRefPubMed Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3 (5): 330-338. 10.1038/nrc1074.CrossRefPubMed
8.
go back to reference Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998, 42 (4): 336-340. 10.1007/s002800050826.CrossRefPubMed Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R: Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998, 42 (4): 336-340. 10.1007/s002800050826.CrossRefPubMed
9.
go back to reference Raymond E, Chaney S, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998, 9 (10): 1053-1071. 10.1023/A:1008213732429.CrossRefPubMed Raymond E, Chaney S, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998, 9 (10): 1053-1071. 10.1023/A:1008213732429.CrossRefPubMed
10.
go back to reference Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-2019. 10.1200/JCO.2007.14.9930.CrossRefPubMed Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008, 26 (12): 2013-2019. 10.1200/JCO.2007.14.9930.CrossRefPubMed
11.
go back to reference Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E: Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish cooperative group for the treatment of digestive tumors. Clin Colorectal Cancer. 2012, 11 (3): 200-206. 10.1016/j.clcc.2012.01.003.CrossRefPubMed Benavides M, Pericay C, Valladares-Ayerbes M, Gil-Calle S, Massutí B, Aparicio J, Dueñas R, González-Flores E, Carrato A, Marcuello E: Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish cooperative group for the treatment of digestive tumors. Clin Colorectal Cancer. 2012, 11 (3): 200-206. 10.1016/j.clcc.2012.01.003.CrossRefPubMed
13.
go back to reference Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin J-C, Ducreux M, Sarasin A, Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005, 11 (17): 6212-6217. 10.1158/1078-0432.CCR-04-2216.CrossRefPubMed Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin J-C, Ducreux M, Sarasin A, Praz F: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2005, 11 (17): 6212-6217. 10.1158/1078-0432.CCR-04-2216.CrossRefPubMed
14.
go back to reference Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55 (7): 1407-1412.PubMed Johnston PG, Lenz H-J, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995, 55 (7): 1407-1412.PubMed
15.
go back to reference Peters G, Backus H, Freemantle S, Van Triest B, Codacci-Pisanelli G, Van der Wilt C, Smid K, Lunec J, Calvert A, Marsh S: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis. 2002, 158 (2): 194-205.CrossRef Peters G, Backus H, Freemantle S, Van Triest B, Codacci-Pisanelli G, Van der Wilt C, Smid K, Lunec J, Calvert A, Marsh S: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis. 2002, 158 (2): 194-205.CrossRef
16.
go back to reference Lecomte T, Ferraz J-M, Zinzindohoué F, Loriot M-A, Tregouet D-A, Landi B, Berger A, Cugnenc P-H, Jian R, Beaune P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004, 10 (17): 5880-5888. 10.1158/1078-0432.CCR-04-0169.CrossRefPubMed Lecomte T, Ferraz J-M, Zinzindohoué F, Loriot M-A, Tregouet D-A, Landi B, Berger A, Cugnenc P-H, Jian R, Beaune P: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004, 10 (17): 5880-5888. 10.1158/1078-0432.CCR-04-0169.CrossRefPubMed
17.
go back to reference Kim K, Yang S, Yoon Y, Lim SB, Yu C, Kim J: Validation of the seventh edition of the American joint committee on cancer tumor‒node‒metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: analysis of 2511 cases from a medical centre in Korea. Colorectal Dis. 2011, 13 (8): e220-e226. 10.1111/j.1463-1318.2011.02625.x.CrossRefPubMed Kim K, Yang S, Yoon Y, Lim SB, Yu C, Kim J: Validation of the seventh edition of the American joint committee on cancer tumor‒node‒metastasis (AJCC TNM) staging in patients with stage II and stage III colorectal carcinoma: analysis of 2511 cases from a medical centre in Korea. Colorectal Dis. 2011, 13 (8): e220-e226. 10.1111/j.1463-1318.2011.02625.x.CrossRefPubMed
18.
go back to reference von Ahlfen S, Missel A, Bendrat K, Schlumpberger M: Determinants of RNA quality from FFPE samples. PLoS One. 2007, 2 (12): e1261-10.1371/journal.pone.0001261.CrossRefPubMedPubMedCentral von Ahlfen S, Missel A, Bendrat K, Schlumpberger M: Determinants of RNA quality from FFPE samples. PLoS One. 2007, 2 (12): e1261-10.1371/journal.pone.0001261.CrossRefPubMedPubMedCentral
19.
go back to reference Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Tsai PI: Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000, 4 (2): 135-142. 10.1016/S1091-255X(00)80049-9.CrossRefPubMed Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Tsai PI: Telomerase reverse transcriptase expression is increased early in the Barrett’s metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 2000, 4 (2): 135-142. 10.1016/S1091-255X(00)80049-9.CrossRefPubMed
20.
go back to reference Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz H-J: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001, 19 (23): 4298-4304.PubMed Shirota Y, Stoehlmacher J, Brabender J, Xiong Y-P, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz H-J: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001, 19 (23): 4298-4304.PubMed
21.
go back to reference Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res. 1996, 6 (10): 986-994. 10.1101/gr.6.10.986.CrossRefPubMed Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome Res. 1996, 6 (10): 986-994. 10.1101/gr.6.10.986.CrossRefPubMed
22.
go back to reference Gibson U, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res. 1996, 6 (10): 995-1001. 10.1101/gr.6.10.995.CrossRefPubMed Gibson U, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res. 1996, 6 (10): 995-1001. 10.1101/gr.6.10.995.CrossRefPubMed
23.
go back to reference Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008, 3 (6): 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008, 3 (6): 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
24.
go back to reference Kwon H, Roh M, Oh S, Kim S, Kim M, Kim J, Kim H: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007, 18 (3): 504-509.CrossRefPubMed Kwon H, Roh M, Oh S, Kim S, Kim M, Kim J, Kim H: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007, 18 (3): 504-509.CrossRefPubMed
25.
go back to reference Kim S-H, Kwon H-C, Oh SY, Lee DM, Lee S, Lee J-H, Roh M-S, Kim D-C, Park K-J, Choi H-J: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009, 32 (1): 38-43. 10.1097/COC.0b013e31817be58e.CrossRefPubMed Kim S-H, Kwon H-C, Oh SY, Lee DM, Lee S, Lee J-H, Roh M-S, Kim D-C, Park K-J, Choi H-J: Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase π for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009, 32 (1): 38-43. 10.1097/COC.0b013e31817be58e.CrossRefPubMed
26.
go back to reference Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG: Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet. 2007, 39 (2): 226-231. 10.1038/ng1955.CrossRefPubMedPubMedCentral Spielman RS, Bastone LA, Burdick JT, Morley M, Ewens WJ, Cheung VG: Common genetic variants account for differences in gene expression among ethnic groups. Nat Genet. 2007, 39 (2): 226-231. 10.1038/ng1955.CrossRefPubMedPubMedCentral
27.
go back to reference Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002, 8 (7): 2286-2291.PubMed Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002, 8 (7): 2286-2291.PubMed
28.
go back to reference Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007, 18 (3): 522-528.CrossRefPubMed Bellmunt J, Paz-Ares L, Cuello M, Cecere F, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007, 18 (3): 522-528.CrossRefPubMed
29.
go back to reference Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Curr Treat Options Oncol. 2000, 48 (4): 1075-1080. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM: Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Curr Treat Options Oncol. 2000, 48 (4): 1075-1080.
30.
go back to reference Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR: Pathologic stage is most prognostic of disease‒free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008, 113 (1): 57-64. 10.1002/cncr.23516.CrossRefPubMed Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, Goodman KA, Minsky BD, Wong WD, Weiser MR: Pathologic stage is most prognostic of disease‒free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008, 113 (1): 57-64. 10.1002/cncr.23516.CrossRefPubMed
Metadata
Title
Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy
Authors
Sheng Li
Liangjun Zhu
Li Yao
Lei Xia
Liangxi Pan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2014
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-14-154

Other articles of this Issue 1/2014

BMC Gastroenterology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.